Search hospitals > New Jersey > Hackensack

Hackensack University Medical Center

Claim this profile
Hackensack, New Jersey 07601
Global Leader in Lymphoma
Global Leader in Leukemia
Conducts research for Cancer
Conducts research for Tumors
Conducts research for Non-Hodgkin's Lymphoma
982 reported clinical trials
53 medical researchers
Photo of Hackensack University Medical Center in HackensackPhoto of Hackensack University Medical Center in HackensackPhoto of Hackensack University Medical Center in Hackensack

Summary

Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Lymphoma, Leukemia, Cancer, Tumors, Non-Hodgkin's Lymphoma and other specialties. Hackensack University Medical Center is involved with conducting 982 clinical trials across 922 conditions. There are 53 research doctors associated with this hospital, such as Martin E Gutierrez, Katharine Offer, Burton E. Appel, and Robert Alter, MD.

Area of expertise

1Lymphoma
Global Leader
Hackensack University Medical Center has run 155 trials for Lymphoma. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Leukemia
Global Leader
Hackensack University Medical Center has run 143 trials for Leukemia. Some of their research focus areas include:
Stage II
Philadelphia chromosome positive
BCR-ABL1 positive

Top PIs

Clinical Trials running at Hackensack University Medical Center

Breast Cancer
Lymphoma
Prostate Cancer
Rhabdomyosarcoma
Acute Lymphoblastic Leukemia
Osteosarcoma
Leukemia
Cancer
Tumors
Bladder Cancer
Image of trial facility.

PF-07220060 + Fulvestrant

for Advanced Breast Cancer

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: are 18 years of age or older; are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; have advanced or metastatic breast cancer after taking other treatments before this study; have not taken or need to take medications that are not allowed by the study protocol; do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: Fulvestrant alone taken as shot into the muscle. Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. the study doctor thinks the participant is no longer benefitting from the study medicine. has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Hackensack University Medical Center?
Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Lymphoma, Leukemia, Cancer, Tumors, Non-Hodgkin's Lymphoma and other specialties. Hackensack University Medical Center is involved with conducting 982 clinical trials across 922 conditions. There are 53 research doctors associated with this hospital, such as Martin E Gutierrez, Katharine Offer, Burton E. Appel, and Robert Alter, MD.
Where is Hackensack University Medical Center located?
To reach Hackensack University Medical Center, located at 30 Prospect Avenue, Hackensack, New Jersey: Take I-80 West to NJ-17 South towards Paramus. Use the right two lanes to exit at 17A-17B for NJ-4 East towards Hackensack. Continue on NJ-4 East, then take the Prospect Avenue exit towards the hospital, which will be on your left.
Who should I call to ask about financial aid or insurance network?
For financial assistance, insurance, and billing inquiries at Hackensack University Medical Center, please call 888-568-3522. To request a copy of the Financial Assistance Policy and Application by mail, contact the Patient Financial Services department at (201) 383-1043. This policy covers all emergency and medically necessary services, including employed physician services and behavioral health.
What insurance does Hackensack University Medical Center accept?
Hackensack University Medical Center accepts a wide range of insurance plans, including but not limited to Aetna, Amerigroup, AmeriHealth, Cigna, Clover, Horizon BCBS, and United HC. The hospital is also part of various networks such as Aetna HMO/PPO, Amerihealth PPO/HMO, Cigna HMO/PPO, Horizon HMO/POS/EPO, and United Healthcare Choice Plus/PPO. Patients are advised to verify their eligibility and coverage directly with their insurance provider, as insurance agreements may change.
What awards or recognition has Hackensack University Medical Center received?
Hackensack University Medical Center, located in Hackensack, New Jersey, has been awarded nearly $1 million in grants by the New Jersey Health Foundation to support research in areas such as cancer, infectious disease, community health, education, diabetes, and rheumatology. It stands out as the only hospital in New Jersey to have both its adult and children's hospitals ranked #1, according to U.S. News & World Report, 2023-24. Furthermore, it is nationally-ranked in six specialties.